Nutriband Inc. 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Nutriband Inc. on July 14, 2025, reporting events that occurred on July 9, 2025. The Company, incorporated in Nevada and trading on The Nasdaq Stock Market LLC under the symbols NTRB (Common Stock) and NTRBW (Warrants), is classified as an emerging growth company.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on corporate governance and capital structure changes rather than financial performance results.
Material Changes
- Amendment to Articles of Incorporation: The Board of Directors approved an amendment to authorize a new series of non-voting shares titled "Series A Convertible Preferred Stock" with a par value of $0.001 per share.
- Authorized Shares: The amendment authorized a total of 2,788,678 shares of Series A Preferred Stock.
- Preferred Stock Dividend: The Board authorized a dividend of one share of Series A Preferred Stock for every four shares of Common Stock owned.
- Record Date: The record date for this dividend is set for July 25, 2025.
Guidance, Outlook, and Contingencies
Conversion Trigger: Each share of Series A Preferred Stock is convertible at the holder's option into one share of Common Stock following the date of FDA approval for commercial sale of the Company's transdermal pharmaceutical products based on its AVERSA abuse deterrent technology.
Dividend Rights: Holders of Series A Preferred Stock who do not convert their shares are eligible for dividends as declared by the Board for the Preferred class and are also eligible for dividends declared on the Common Stock class.
Management Commentary: The filing does not contain specific management commentary regarding future financial guidance or operational outlook beyond the structural changes described.
Investor Verification Checklist
- Verify the exact number of Common Stock shares outstanding as of the July 25, 2025 record date to calculate the total issuance of Series A Preferred Stock.
- Confirm the current regulatory status of the Company's AVERSA technology with the FDA to assess the likelihood and timing of the conversion trigger.
- Review the full text of the Certificate of Amendment (Exhibit 3.1D) for any additional rights, preferences, or restrictions attached to the Series A Preferred Stock.
- Monitor subsequent filings for the declaration of any dividends on the new Preferred Stock class.